Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial

•Whether PK-guided pembrolizumab in advanced NSCLC is a rational therapeutic strategy.•Pembrolizumab administration under PK-guided was an alternative rational strategy.•Personalized optimal treatment of pembrolizumab can reduce economic toxicity. Pembrolizumab is recommended with a fixed dose of 20...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2023-04, Vol.178, p.183-190
Hauptverfasser:	Wang, Na, Zheng, Lie, Li, Meichen, Hou, Xue, Zhang, Baishen, Chen, Jing, Li, Su, Chen, Likun
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced non-small cell lung cancer Antineoplastic Combined Chemotherapy Protocols - adverse effects Carcinoma, Non-Small-Cell Lung Drug administration schedule Humans Infant, Newborn Lung Neoplasms - drug therapy Lung Neoplasms - genetics Neonatal Fc receptors Pembrolizumab Pharmacokinetic Prospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!